JP2023507885A5 - - Google Patents
Info
- Publication number
- JP2023507885A5 JP2023507885A5 JP2022526717A JP2022526717A JP2023507885A5 JP 2023507885 A5 JP2023507885 A5 JP 2023507885A5 JP 2022526717 A JP2022526717 A JP 2022526717A JP 2022526717 A JP2022526717 A JP 2022526717A JP 2023507885 A5 JP2023507885 A5 JP 2023507885A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- virus
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934345P | 2019-11-12 | 2019-11-12 | |
| US62/934,345 | 2019-11-12 | ||
| PCT/US2020/060288 WO2021097131A1 (en) | 2019-11-12 | 2020-11-12 | Compositions and methods for treating or preventing crohn's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507885A JP2023507885A (ja) | 2023-02-28 |
| JP2023507885A5 true JP2023507885A5 (https=) | 2023-11-20 |
Family
ID=75912891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526717A Pending JP2023507885A (ja) | 2019-11-12 | 2020-11-12 | クローン病の治療または予防のための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220370509A1 (https=) |
| EP (1) | EP4058043A4 (https=) |
| JP (1) | JP2023507885A (https=) |
| CN (1) | CN115087455A (https=) |
| AU (1) | AU2020383510A1 (https=) |
| CA (1) | CA3160799A1 (https=) |
| WO (1) | WO2021097131A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114958917A (zh) * | 2022-06-21 | 2022-08-30 | 赛业（苏州）生物科技有限公司 | 一种克罗恩病小鼠动物模型的构建方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040053263A1 (en) * | 2002-08-30 | 2004-03-18 | Abreu Maria T. | Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease |
| WO2005115135A2 (en) * | 2004-04-09 | 2005-12-08 | The Regents Of The University Of California | Mouse model of crohn’s disease and a method to develop specific therapeutics |
| WO2006116867A1 (en) * | 2005-04-29 | 2006-11-09 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| GB0603427D0 (en) * | 2006-02-21 | 2006-04-05 | Ucl Biomedica Plc | IL-8 Therapy |
| EP2049691A4 (en) * | 2006-07-26 | 2010-06-16 | Genizon Biosciences Inc | SUSCEPTIBILITY TREASURES FOR MORBUS CROHN |
| WO2008070564A1 (en) * | 2006-12-01 | 2008-06-12 | The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services | Uses of muramyl dipeptide (mdp) for treating inflammation |
| US20120046329A1 (en) * | 2010-08-10 | 2012-02-23 | Sanford-Burnham Medical Research Institute | Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof |
| US20170007668A1 (en) * | 2010-08-23 | 2017-01-12 | Kang Stem Biotech Co., Ltd | Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases |
| EP2620156B1 (en) * | 2010-08-23 | 2019-03-27 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof |
| WO2013125899A1 (ko) * | 2012-02-22 | 2013-08-29 | 주식회사 강스템홀딩스 | 줄기세포를 유효 성분으로 함유하는 면역 질환 또는 염증 질환의 예방 또는 치료용 조성물 |
| CN106573056A (zh) * | 2014-07-28 | 2017-04-19 | 诺格尔制药有限公司 | 用于诊断和治疗炎症性肠病的方法和组合物 |
| TW201717968A (zh) * | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| JP2021517168A (ja) * | 2018-03-09 | 2021-07-15 | アブロバイオ，インコーポレーテッド | パーキンソン病を処置するための組成物及び方法 |
-
2020
- 2020-11-12 CN CN202080089510.4A patent/CN115087455A/zh active Pending
- 2020-11-12 JP JP2022526717A patent/JP2023507885A/ja active Pending
- 2020-11-12 CA CA3160799A patent/CA3160799A1/en active Pending
- 2020-11-12 US US17/771,524 patent/US20220370509A1/en active Pending
- 2020-11-12 EP EP20887937.9A patent/EP4058043A4/en active Pending
- 2020-11-12 AU AU2020383510A patent/AU2020383510A1/en active Pending
- 2020-11-12 WO PCT/US2020/060288 patent/WO2021097131A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2577982C2 (ru) | Полустабильное получение лентивирусных векторов | |
| US8058061B2 (en) | Vector encoding human globin gene and use thereof in treatment of hemoglobinopathies | |
| CN118581154A (zh) | 用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法 | |
| US20020131961A1 (en) | Method for gene transfer using Bcl2 and compositions useful therein | |
| JP7623299B2 (ja) | 乳児性悪性大理石骨病に対する遺伝子療法ベクター | |
| IL110182A (en) | A retroviral issue for transferring genes and inserting them for medical purposes into eukaryotic cells | |
| US20090148425A1 (en) | Therapeutic method for blood coagulation disorder | |
| Miyake et al. | Stable integration of human immunodeficiency virus-based retroviral vectors into the chromosomes of nondividing cells | |
| Gould et al. | Vectors for the treatment of autoimmune disease | |
| AU2015315726A1 (en) | Lentiviral vector for treating hemoglobin disorders | |
| KR101891626B1 (ko) | 렌티바이러스 벡터의 반-안정성 산물 | |
| JP2023544633A (ja) | 治療における使用のためのｒａｇ１の置き換え | |
| TW202129002A (zh) | 用於myh7關聯之心肌病之基因療法組合物及治療 | |
| JP2023507885A5 (https=) | ||
| Douglas et al. | Efficient human immunodeficiency virus-based vector transduction of unstimulated human mobilized peripheral blood CD34+ cells in the SCID-hu Thy/Liv model of human T cell lymphopoiesis | |
| Hanawa et al. | High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells | |
| WO2008136656A1 (en) | Improved methods and means for lentiviral gene delivery | |
| CN116635523A (zh) | 用于疗法中的rag1的替代物 | |
| WO2017156057A1 (en) | Retroviral construct harboring a let-7 insensitive nucleic acid encoding hmga2 and methods of use thereof | |
| Hanazono et al. | Primary T lymphocytes as targets for gene therapy | |
| Moritz et al. | Methods for gene transfer: genetic manipulation of hematopoietic stem cells | |
| Еpifanova et al. | Viral Vectors for Delivering Gene Material into Cells and Their Application in Neurobiology | |
| Klein | Advances in viral vector design: Tissue-and cell-type specific promoters can improve the safety and efficacy of lentiviral gene therapy | |
| WO2025215591A1 (en) | Modified vectors for xla gene therapy | |
| Verma | Gene Therapy: Medicine of the 21stCentury |